The article amendments section includes three corrigenda: 1. **Griscelli Syndrome**: The authors correct an error in the methods section regarding the numbering of two patients, clarifying that the clinical presentation of patients A and B (PA and PB) has been previously reported. 2. **Toll-like Receptor 9–Induced Type I IFN**: The authors correct an incorrect reference number in the methods section, providing the correct reference for a study on the role of phosphatidylinositol 3 kinase in CpG DNA-induced immune activation. 3. **Liver Fibrosis**: The authors correct a listing in Table 2, stating that PPARγ agonists, not PPAR antagonists, have shown inhibitory effects on HSCs and antifibrotic effects in animal models of liver fibrosis and patients with NASH.The article amendments section includes three corrigenda: 1. **Griscelli Syndrome**: The authors correct an error in the methods section regarding the numbering of two patients, clarifying that the clinical presentation of patients A and B (PA and PB) has been previously reported. 2. **Toll-like Receptor 9–Induced Type I IFN**: The authors correct an incorrect reference number in the methods section, providing the correct reference for a study on the role of phosphatidylinositol 3 kinase in CpG DNA-induced immune activation. 3. **Liver Fibrosis**: The authors correct a listing in Table 2, stating that PPARγ agonists, not PPAR antagonists, have shown inhibitory effects on HSCs and antifibrotic effects in animal models of liver fibrosis and patients with NASH.